Tan Lynnette R L, Tiong Ho Yee
Department of Urology, National University Hospital, Singapore.
ANZ J Surg. 2019 Jul;89(7-8):930-934. doi: 10.1111/ans.14828. Epub 2019 Jan 26.
In patients with bladder augmentation undergoing kidney transplantation, conventional technique recommends anastomosing the transplanted ureter to the bladder. We report our technique of ureteric implantation into the bowel portion of the enterocystoplasty, and review the urological outcomes of transplantation in these patients.
Seven patients (mean age: 26 years (range 24-54 years), two females, five deceased donors) with augmented cystoplasty and subsequent kidney transplantation by a single surgeon from 2011 to 2015 were reviewed. Following standard vascular anastomosis and reperfusion of the transplanted kidney, ureteric implantation involved continuous 5/0 polydiaoxanone anastomosis between the spatulated ureter and full thickness bowel portion of the cystoplasty over a 6-Fr double J stent. A second peri-anastomosis layer of bowel plication was performed to prevent reflux using interrupted 3/0 vicryl sutures. Short-term urological and kidney function outcomes were evaluated.
Causes of renal failure included: posterior urethral valve with reflux nephropathy (two patients), bilateral vesicoureteric reflux (two patients), lumbosacral agenesis with neurogenic bladder (one patient), tuberculosis of the urinary tract with post-infective ureteric stricture (one patient), and lupus nephritis (one patient). Bladder reconstruction was performed at median duration of 103 months (35-171 months) before transplantation. Gastrocystoplasty was performed in two patients while colon and/or ileum were used in the remaining six. After transplantation, all reconstructed bladders except one had a Mitrofanoff for clean intermittent self-catheterization, 5-8 times per day. There were no post-operative ureteric/surgical complications. Delayed graft function occurred in three of seven patients. 30-day asymptomatic bacteriuria rate was three out of seven after stent removal. 1-year post-transplantation, patient and graft survival were 100%. Mean serum creatinine was 142.7 (standard deviation: 51.48). Median number of hospital admissions for urinary tract infections was 0.225 (range 0-0.40). Over a median follow-up period of 4 years (2-7 years), one graft failed from acute T-cell-mediated rejection. This patient passed away from cardio-respiratory collapse after a seizure, 35 months post-transplantation. As of June 2018, the other six kidney grafts were functioning. No complications including calculi formation and/or malignancy were reported.
In patients with previously augmented bladders now undergoing kidney transplantation, ureteric implantation into the bowel portion of the cystoplasty appears to be safe.
在接受肾移植的膀胱扩大术患者中,传统技术建议将移植的输尿管与膀胱进行吻合。我们报告了将输尿管植入回肠膀胱扩大术肠段的技术,并回顾了这些患者移植后的泌尿系统结局。
回顾了2011年至2015年由同一位外科医生进行膀胱扩大术并随后进行肾移植的7例患者(平均年龄:26岁(范围24 - 54岁),2名女性,5名已故供体)。在对移植肾进行标准的血管吻合和再灌注后,输尿管植入包括在6F双J支架上,将修剪成斜面的输尿管与膀胱扩大术的全层肠段进行连续的5/0聚二氧六环酮吻合。使用间断的3/0薇乔缝线进行第二层肠吻合周围的肠襞叠缩以防止反流。评估短期泌尿系统和肾功能结局。
肾衰竭的病因包括:后尿道瓣膜伴反流性肾病(2例)、双侧膀胱输尿管反流(2例)、腰骶部发育不全伴神经源性膀胱(1例)、尿路感染伴感染后输尿管狭窄(1例)和狼疮性肾炎(1例)。移植前膀胱重建的中位时间为103个月(35 - 171个月)。2例患者进行了胃膀胱扩大术,其余6例使用结肠和/或回肠。移植后,除1例重建膀胱外,其余所有膀胱均有一个用于清洁间歇性自我导尿的米氏可控性尿流改道术,每天5 - 8次。无术后输尿管/手术并发症。7例患者中有3例发生移植肾功能延迟恢复。支架取出后,7例中有3例30天无症状菌尿率。移植后1年,患者和移植物存活率均为100%。平均血清肌酐为142.7(标准差:51.48)。尿路感染住院的中位次数为0.225(范围0 - 0.40)。在中位随访期4年(2 - 7年)内,1例移植物因急性T细胞介导的排斥反应失败。该患者在移植后35个月因癫痫发作后心肺功能衰竭死亡。截至2018年6月,其他6例肾移植功能良好。未报告包括结石形成和/或恶性肿瘤在内的并发症。
在先前接受膀胱扩大术现正接受肾移植的患者中,将输尿管植入膀胱扩大术的肠段似乎是安全的。